Discontinuities and senior management: assessing the role of recognition in pharmaceutical firm response to biotechnology
Despite an increasing emphasis on the role of senior management cognition in shaping organizational action, there have been few attempts to link top management mental models to strategic choice in the face of discontinuous innovation. This paper uses 23 years of data covering 15 major pharmaceutical firms to explore the degree to which each firm's response to the revolution in biotechnology was shaped by the senior team's recognition of biotechnology's importance. Controlling for a number of important alternative explanations, we show that recognition may be an important predictor of action, suggesting that cognition at the most senior level can play a critical role in shaping established firms' response to discontinuities. Copyright 2003, Oxford University Press.
To our knowledge, this item is not available for
download. To find whether it is available, there are three
1. Check below under "Related research" whether another version of this item is available online.
2. Check on the provider's web page whether it is in fact available.
3. Perform a search for a similarly titled item that would be available.
Volume (Year): 12 (2003)
Issue (Month): 2 (April)
|Contact details of provider:|| Postal: Oxford University Press, Great Clarendon Street, Oxford OX2 6DP, UK|
Fax: 01865 267 985
Web page: http://icc.oupjournals.org/
|Order Information:||Web: http://www.oup.co.uk/journals|
When requesting a correction, please mention this item's handle: RePEc:oup:indcch:v:12:y:2003:i:2:p:203-233. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Oxford University Press)or (Christopher F. Baum)
If references are entirely missing, you can add them using this form.